Declan McGuone, FRCPath Neuro, MBBCh
Associate Professor of PathologyDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
Yale School of Medicine
310 Cedar Street BML254-C
New Haven, CT 06510
United States
About
Titles
Associate Professor of Pathology
Appointments
Pathology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Fellow (Forensic Pathology)
- New York City Office of the Chief Medical Examiner
- Resident (Anatomic Pathology)
- Massachusetts General Hospital
- Fellow (Neuropathology)
- Massachusetts General Hospital
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Declan McGuone's published research.
Publications Timeline
A big-picture view of Declan McGuone's research output by year.
Sacit Bulent Omay, MD, FAANS
Kanat Yalcin, MD
Murat Günel, MD, FACS, FAHA, FAANS
Ketu Mishra-Gorur, MSc, MS, PhD
Zeynep Erson Omay, PhD
Nicholas Blondin, MD
64Publications
921Citations
Publications
2024
EPCO-35. GENOMIC CHARACTERIZATION OF GROWTH HORMONE SECRETING PITUITARY ADENOMAS
Alanya H, Yalcin K, Hilton B, Gultekin B, Mishra-Gorur K, McGuone D, Gunel M, Omay S, Erson-Omay Z. EPCO-35. GENOMIC CHARACTERIZATION OF GROWTH HORMONE SECRETING PITUITARY ADENOMAS. Neuro-Oncology 2024, 26: viii9-viii9. PMCID: PMC11553213, DOI: 10.1093/neuonc/noae165.0034.Peer-Reviewed Original ResearchConceptsGH-secreting pituitary adenomasWhole-exome sequencingPituitary adenomasGNAS mutationsCopy number variationsSporadic GH-secreting pituitary adenomasGrowth hormone (GH)-secreting pituitary adenomasGenomic profilingGrowth hormone secreting pituitary adenomaSecreting pituitary adenomasBlood samplesComprehensive genomic characterizationSomatic GNAS mutationsSingle nucleotide variantsMatched blood samplesGenomic instabilityAssessment of genomic instabilityStatistically significant differenceTumor sizeClinical featuresTumor samplesClinical dataTumorExome sequencingBrain tumorsExploiting blood-based biomarkers to align preclinical models with human traumatic brain injury
Lisi I, Moro F, Mazzone E, Marklund N, Pischiutta F, Kobeissy F, Mao X, Corrigan F, Helmy A, Nasrallah F, Di Pietro V, Ngwenya L, Portela L, Semple B, Schneider A, Diaz Arrastia R, Menon D, Smith D, Wellington C, Loane D, Wang K, Zanier E, Abbasloo E, Agrawal A, Anwer M, Anyaegbu C, Caeyenberghs K, Collins L, Corrigan F, Cowen G, Portela L, Cullen J, D'Alonzo B, Di Pietro V, Keene C, Esser M, Giersztein S, Helmy A, Hoffman S, Iacono D, Jha R, Johnson V, Justus J, Keene C, Lins B, Liebel S, Loane D, Mao X, Marklund N, McCrea M, McGuone D, Mohamed A, Moro F, Mychasiuk R, Nagarajan G, Nasrallah F, Ngum P, Ngwenya L, Oteng R, Parihar A, Phillips J, Pischiutta F, Prakash S, Robba C, Rostami E, Roselli F, Semple B, Shultz S, Smith D, Song H, Stefani M, Stewart W, Verma R, Wang K, Wellington C, Winston B, Zanier E. Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury. Brain 2024, awae350. PMID: 39514789, DOI: 10.1093/brain/awae350.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryPreclinical modelsPreclinical studiesRodent modelsUCH-L1Experience traumatic brain injuriesBrain injuryReal world clinical practiceTranslation of drugsPost-injuryClinically relevant biomarkersPathophysiology of traumatic brain injuryHuman traumatic brain injuryWhite matter lossDose optimizationBlood-based biomarkersMedian quality scoreTreatment initiationTBI studiesTherapeutic decisionsDrug dose optimizationPharmacodynamic responseChronic phaseBlood levelsClinical trialsRocky Mountain Spotted Fever Encephalitis and "Starry Sky" Pattern on MRI: A Case Report.
Mikhaiel J, Parasram M, Park J, Cappucci S, McGuone D, Falcone G, Sheth K, Gilmore E. Rocky Mountain Spotted Fever Encephalitis and "Starry Sky" Pattern on MRI: A Case Report. The Neurologist 2024 PMID: 39382206, DOI: 10.1097/nrl.0000000000000586.Peer-Reviewed Original ResearchAltmetricConceptsMagnetic resonance imagingPetechial rashCase reportDiffusion restrictionMagnetic resonance imaging brainMagnetic resonance imaging brain findingsRepeat MRI brainRocky Mountain spotted feverUrinary tract infectionFoci of diffusion restrictionRight centrum semiovaleProgression to comaPerivascular lymphocytic infiltrateDiffuse petechial rashTract infectionsClinical presentationViral cultureClinical improvementMRI brainLymphocytic infiltrationLumbar punctureSkin biopsiesElevated proteinNeurological manifestationsPunctate fociBSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE
Kandigian S, Chande S, Dolezal D, Tang T, Wang D, Arnal-Estapé A, Cheok S, McGuone D, Liu Y, Goldberg S, Blondin N, Chiang V, Nguyen D. BSLM-10 MOLECULAR AND HISTOLOGICAL CHARACTERIZATION OF NSCLC PROGRESSION TO LEPTOMENINGEAL METASTASIS WITH COMORBID INTRAPARENCHYMAL DISEASE. Neuro-Oncology Advances 2024, 6: i7-i7. PMCID: PMC11296776, DOI: 10.1093/noajnl/vdae090.020.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLeptomeningeal diseaseCentral nervous systemLeptomeningeal metastasesParenchymal metastasesCerebrospinal fluidTumor cellsTyrosine kinase inhibitor treatmentCell lung cancerKinase inhibitor treatmentCerebrospinal fluid of patientsCell linesCerebral lateral ventriclesIntra-arterial injectionTGF-b signalingIn vivo passageIntraparenchymal diseaseMechanisms of progressionTumor microenvironmentMultiplex immunofluorescenceAggressive treatmentLeptomeningeal infiltrationPerivascular invasionIntraparenchymal metastasesMurine modelHeterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas
Tabor J, O'Brien J, Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas. Neurosurgery 2024, 70: 203-203. DOI: 10.1227/neu.0000000000002810_112.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-grade meningiomasOverall survivalNF2 mutationsDecreased PFSLow grade meningiomasWHO grading criteriaLow-grade meningiomasAssociated with recurrenceSomatic NF2 mutationsHigher recurrence rateSomatic driver mutationsAggressive clinical characteristicsIncreased chromosomal instabilityLoss of CDKN2A/BHigh-copy number variationCDKN2A mutationsCopy number variationsAggressive meningiomasLow-grade onesProliferative indexCDKN2A lossGrade meningiomasRecurrence rateMitotic countVariations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.
Tabor J, Dincer A, O'Brien J, Lei H, Vetsa S, Vasandani S, Jalal M, Yalcin K, Morales-Valero S, Marianayagam N, Alanya H, Elsamadicy A, Millares Chavez M, Aguilera S, Mishra-Gorur K, McGuone D, Fulbright R, Jin L, Erson-Omay E, Günel M, Moliterno J. Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group. Journal Of Neurosurgery 2024, 141: 664-672. PMID: 38518289, DOI: 10.3171/2024.1.jns231633.Peer-Reviewed Original ResearchAltmetricConceptsBlack patientsSporadic meningiomasClinical outcomesGenomic profilingClinical behavior of meningiomasShorter progression-free survivalAnterior skull base tumorsClinical data of patientsHispanic patientsProgression-free survivalChromosome 1p deletionBehavior of meningiomasIncreased recurrence rateRate of recurrenceSkull base tumorsData of patientsSomatic driver mutationsNon-Black patientsShorter PFSOverall survivalAggressive meningiomasTRAF7 mutationsIntracranial meningiomasMeningioma resectionNon-black group
2023
Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury
Kapate N, Liao R, Sodemann R, Stinson T, Prakash S, Kumbhojkar N, Suja V, Wang L, Flanz M, Rajeev R, Villafuerte D, Shaha S, Janes M, Park K, Dunne M, Golemb B, Hone A, Adebowale K, Clegg J, Slate A, McGuone D, Costine-Bartell B, Mitragotri S. Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury. PNAS Nexus 2023, 3: pgad434. PMID: 38187808, PMCID: PMC10768983, DOI: 10.1093/pnasnexus/pgad434.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTraumatic brain injuryBrain injuryAnti-inflammatory interleukin-4Cortical impact (CCI) TBI modelCell therapyAcute clinical managementDysregulated inflammatory responseSecondary brain injuryAnti-inflammatory phenotypeBrain lesion siteImmune cell therapyRole of macrophagesLarge animal modelUnique therapeutic potentialWound-healing phenotypeRampant inflammationProinflammatory biomarkersTBI modelImmunomodulatory effectsInflammation modulationCurrent therapiesMacrophage-based therapiesNeuroprotection mechanismsProinflammatory activationSerum concentrationsEPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS
Tabor J, Chavez M, O'Brien J, Morales-Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. EPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS. Neuro-Oncology 2023, 25: v134-v135. PMCID: PMC10639255, DOI: 10.1093/neuonc/noad179.0509.Peer-Reviewed Original ResearchConceptsProgression-free survivalShorter progression-free survivalHigh recurrence rateHigh-grade meningiomasCDKN2A/BOverall survivalRecurrence rateLow-grade meningiomasHeterozygous lossNF2 mutationsHigh mitotic countFree survivalMethods ClinicalSomatic NF2 mutationsClinical associationsLower OSHigh recurrenceLow-grade onesProliferative indexMitotic countAggressive meningiomasClinical implicationsMeningiomasPotential associationSkull baseA PILOT STUDY: SPATIOTEMPORALLY-RESOLVED MOLECULAR MECHANISMS OF ACUTE IMMUNE AND NEUROMODULATORY RESPONSES TO TRAUMATIC BRAIN INJURY
Mohammed F, Mcguone D, Omay S, Omay Z, Zhou J. A PILOT STUDY: SPATIOTEMPORALLY-RESOLVED MOLECULAR MECHANISMS OF ACUTE IMMUNE AND NEUROMODULATORY RESPONSES TO TRAUMATIC BRAIN INJURY. IBRO Neuroscience Reports 2023, 15: s189-s190. DOI: 10.1016/j.ibneur.2023.08.289.Peer-Reviewed Original ResearchThe clinical and genomic features of seizures in meningiomas
Dincer A, Jalal M, Gupte T, Vetsa S, Vasandani S, Yalcin K, Marianayagam N, Blondin N, Corbin Z, McGuone D, Fulbright R, Erson-Omay Z, Günel M, Moliterno J. The clinical and genomic features of seizures in meningiomas. Neuro-Oncology Advances 2023, 5: i49-i57. PMID: 37287582, PMCID: PMC10243847, DOI: 10.1093/noajnl/vdac110.Peer-Reviewed Original ResearchCitationsConceptsPeritumoral brain edemaPostoperative seizuresBrain invasionSubtotal resectionBrain edemaLarge residual tumor volumeCentral nervous system tumorsCommon central nervous system tumorPersistent postoperative seizuresResidual tumor volumeHistory of seizuresHigh tumor gradeNervous system tumorsQuality of lifePreoperative seizuresAtypical histologyMost patientsSurgical resectionCortical hyperexcitabilityUncontrolled seizuresAggressive featuresSeizure activityEpileptogenic focusCortical irritationRisk factors
Clinical Care
Overview
Clinical Specialties
Anatomic Pathology; Autopsy Pathology; Neuropathology
Board Certifications
Forensic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2016
Anatomic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2015
Neuropathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2015
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
310 Cedar Street BML254-C
New Haven, CT 06510
United States